Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Bird & Bird targets Nordic life sciences growth with regulatory hire
Careers
The firm brings in a former Plesner director and Novo Nordisk in-house counsel with regulatory and compliance expertise.   5 January 2026
Key EU and UK regulatory changes to watch for in 2026
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.   5 January 2026
PTAB year in review: A shifting landscape and outlook for 2026
Americas
With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.   2 January 2026
Europe
As the Unified Patent Court continues in its third year, there are inevitable issues that continue to arise as it grows as a jurisdiction, writes Darren Smyth of EIP.   31 December 2025
Europe
The Life in the Law 2025 report sheds light on the mental health challenges faced by legal professionals, revealing the links between wellbeing, inclusion and modern working practices. IP Inclusive’s Andrea Brewster explores how the findings offer clear guidance for meaningful change.   30 December 2025
Europe
Edwards v Meril, Teva and the FTC, and modified jury verdicts—lawyers from WilmerHale provide a review of the key cases of the year and their implications.   29 December 2025
Europe
As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.   24 December 2025
Americas
John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.   24 December 2025
Europe
Europe’s life sciences sector is getting a major overhaul. A spate of reforms promises faster approvals, less red tape, and more innovation, reports Marisa Woutersen.   23 December 2025
Americas
Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.   22 December 2025